Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma

European Journal of Haematology

Volumn 66, Issue 5, 2001, Pages 328-336

  Gulbrandsen, Nina ^a   Wisløff, Finn ^a   Nord, Erik ^b   Lenhoff, Stig ^c   Hjorth, Martin ^d   Westin, Jan ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Lidkoping Hospital   (Sweden)

Author keywords

Adult; Antineoplastic agents; Cost benefit analysis; Hematopoetic stem cell transplantation; Melphalan; Multiple myeloma; Prospective studies; Quality adjusted life years

Indexed keywords

ALPHA2B INTERFERON; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SURVIVAL TIME;

EID: 0034976101     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.066005328.x     Document Type: Article

References (30)

1. Measurement of health related quality of life in multiple myeloma
2. Survival in conventionally treated younger (< 60 years) multiple myeloma patients: No improvement during two decades
3. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6633 patients from 27 randomized trials
4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
5. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
6. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 yr with newly diagnosed multiple myeloma: A population-based study
7. Health related quality of life of multiple myeloma patients treated with high dose chemotherapy and autologous peripheral blood stem cell transplantation
8. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma
9. Effect of interferon on the health-related quality of life of multiple myeloma patients: Results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + α-interferon
10. Cost-utility analysis of melphalan plus prednisone with or without Interferon-α2b in newly diagnosed multiple myeloma
11. The friction cost method for measuring indirect costs of disease
12. The European Organization for Research and Treatment of Cancer QLQ C-30: A quality of life instrument for use in international clinical trials in oncology
13. Methods for quality adjustment of life years
14. Social evaluation of health care vs personal valuation of health states
15. The validity of using health state indexes in measuring the consequences of traffic injury for public health
16. Health status index models for use in resource allocation decision: A critical review in the light of observed preferences for social choice
17. A fifteen-dimensional measure of health related quality of life (15D) and its applications
18. Costs of intensive treatment and follow-up of patients with multiple myeloma
19. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma
20. Treatments for newly diagnosed multiple myeloma: Analysis of survival data and cost-effectiveness evaluation
21. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia
22. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia
23. HOW attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations
24. Towards quality assurance in QALY calculations
25. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma
26. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: Long-term follow-up results